International Clinical Trial: The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07203729) titled 'The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis' on Sept. 25.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Condition: HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis

Intervention: Drug: Trastuzumab Rezetecan

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: Nov...